PepGen slumps as FDA places hold on lead drug Shares in PepGen fell sharply after the FDA placed a partial clinical hold on its lead drug for rare neuromuscular disease DM1.

#Shares in #PepGen were down more than 21% after the #FDA placed a #partialclinicalhold on its lead drug PGN-EDODM1, for rare genetic muscle disorder #myotonicdystrophytype1 (DM1).

Faruqi & Faruqi Urges PepGen Investors to Act Before Lawsuit Deadline in 2025 PepGen investors are reminded of the upcoming deadline for a pending class action lawsuit, as Faruqi & Faruqi advocates legal action for those affected by the company's misstatements.

Faruqi & Faruqi Urges PepGen Investors to Act Before Lawsuit Deadline in 2025 #United_States #New_York #Faruqi_&_Faruqi #PEPG #PepGen

Faruqi & Faruqi, LLP Leads Investigation into PepGen Inc. Securities Fraud Case Faruqi & Faruqi, a nationally recognized law firm, is examining claims related to PepGen Inc., urging affected investors to step forward and take action.

Faruqi & Faruqi, LLP Leads Investigation into PepGen Inc. Securities Fraud Case #United_States #New_York #Faruqi_&_Faruqi #PEPG #PepGen

Pomerantz Law Firm Files Class Action Against PepGen Inc. Over Alleged Securities Violations Pomerantz LLP has launched a class action lawsuit against PepGen Inc., alleging violations of federal securities laws. Investors may recover damages before the deadline.

Pomerantz Law Firm Files Class Action Against PepGen Inc. Over Alleged Securities Violations #New_York #US #Pomerantz_LLP #PGN-EDO51 #PepGen

PepGen Inc. Investors Notified of Class Action Lawsuit with Key Deadline Approaching PepGen Inc. shareholders are alerted about the pending class action lawsuit against the company. Key deadline for lead plaintiffs is August 8, 2025.

PepGen Inc. Investors Notified of Class Action Lawsuit with Key Deadline Approaching #United_States #New_York #Securities #ClassAction #PepGen

Faruqi & Faruqi Launches Investigation Into PepGen Amid Shareholder Concerns Faruqi & Faruqi, LLP is actively looking into claims from PepGen investors who suffered substantial losses from March 2024 to March 2025.

Faruqi & Faruqi Launches Investigation Into PepGen Amid Shareholder Concerns #United_States #New_York #Faruqi_&_Faruqi #PEPG #PepGen

Class Action Filed Against PepGen Inc. by Pomerantz Law Firm Over Securities Violations Pomerantz LLP has initiated a class action lawsuit against PepGen Inc. and certain officers, alleging violations of federal securities laws during the class period.

Class Action Filed Against PepGen Inc. by Pomerantz Law Firm Over Securities Violations #United_States #New_York #Class_Action #Pomerantz_LLP #PepGen

Join the Class Action Lawsuit Against PepGen Inc. by August 2025 Shareholders of PepGen Inc. are encouraged to join a class action lawsuit regarding significant allegations against the company before the August 8, 2025 deadline.

Join the Class Action Lawsuit Against PepGen Inc. by August 2025 #United_States #New_York #Class_Action #Gross_Law_Firm #PepGen

Schall Law Firm Encourages PepGen Investors to Join Class Action Lawsuit PepGen Inc. investors are urged by the Schall Law Firm to join a class action lawsuit for alleged securities fraud. Contact before the deadline for representation.

Schall Law Firm Encourages PepGen Investors to Join Class Action Lawsuit #United_States #Los_Angeles #Schall_Law_Firm #PepGen_Inc #PepGen

Faruqi & Faruqi Urges PepGen Investors to Act Amid Class Action Lawsuit Deadline Faruqi & Faruqi, LLP advises PepGen investors about a forthcoming class action lawsuit with a crucial lead plaintiff deadline approaching on August 11, 2025.

Faruqi & Faruqi Urges PepGen Investors to Act Amid Class Action Lawsuit Deadline #United_States #New_York #Faruqi_&_Faruqi #PEPG #PepGen

Investors in PepGen Inc. Urged to Join Class Action Lawsuit Against Securities Fraud Investors in PepGen Inc. have a crucial opportunity to join a class action lawsuit for alleged securities fraud. The Schall Law Firm leads this effort.

Investors in PepGen Inc. Urged to Join Class Action Lawsuit Against Securities Fraud #United_States #Los_Angeles #Schall_Law_Firm #Securities_Fraud #PepGen

Investors of PepGen Inc. Should Consider Legal Action for Securities Fraud Today Investors who purchased securities of PepGen Inc. between March 7, 2024, and March 3, 2025, are urged to join a lawsuit highlighting alleged securities fraud by the company.

Investors of PepGen Inc. Should Consider Legal Action for Securities Fraud Today #USA #Los_Angeles #Schall_Law_Firm #Securities_Fraud #PepGen

Investors Have Chance to Lead PepGen Securities Fraud Case with Faruqi & Faruqi, LLP Faruqi & Faruqi, LLP is urging investors impacted by PepGen's alleged securities fraud to act, as the deadline for lead plaintiff applications approaches.

Investors Have Chance to Lead PepGen Securities Fraud Case with Faruqi & Faruqi, LLP #United_States #New_York #Securities_Fraud #Faruqi_&_Faruqi #PepGen

Faruqi & Faruqi Partners with PEPG Investors in Legal Action Against PepGen Securities Fraud Faruqi & Faruqi, a prominent law firm, is launching an investigation into PepGen Inc. regarding potential securities fraud. Investors are encouraged to act quickly.

Faruqi & Faruqi Partners with PEPG Investors in Legal Action Against PepGen Securities Fraud #United_States #New_York #Faruqi_&_Faruqi #PEPG #PepGen

PEPG Investors Encouraged to Participate in PepGen Inc. Class Action Lawsuit The Rosen Law Firm urges investors of PepGen Inc. to join a class action lawsuit by the August 8, 2025 deadline for possible compensation.

PEPG Investors Encouraged to Participate in PepGen Inc. Class Action Lawsuit #USA #New_York #Securities_Fraud #Rosen_Law #PepGen

Class Action Lawsuit Filed Against PepGen Inc. and Its Officials Over Alleged Securities Violations Pomerantz Law Firm has initiated a class action lawsuit against PepGen Inc. and its officers, citing serious violations of federal securities laws. Investors from the Class Period may seek compensation.

Class Action Lawsuit Filed Against PepGen Inc. and Its Officials Over Alleged Securities Violations #United_States #New_York #Pomerantz #PGN-EDO51 #PepGen

Faruqi & Faruqi Highlights Class Action Against PepGen with Deadline Approaching in 2025 Faruqi & Faruqi LLP alerts investors about essential class action lawsuit deadlines regarding PepGen. Affected investors should act swiftly.

Faruqi & Faruqi Highlights Class Action Against PepGen with Deadline Approaching in 2025 #United_States #New_York #Class_Action #Faruqi_&_Faruqi #PepGen

PepGen Inc. Investors Alert: Class Action Lawsuit Filed for Recovery of Losses Investors of PepGen Inc. may lead a class action lawsuit due to alleged misleading statements that have resulted in significant losses for shareholders.

PepGen Inc. Investors Alert: Class Action Lawsuit Filed for Recovery of Losses #United_States #New_York #Class_Action #Bronstein_Law #PepGen

Schall Law Firm Invites PEPG Investors to Participate in Class Action Against PepGen Inc. Investors impacted by PepGen Inc.'s misleading statements during a class action period are encouraged to join the lawsuit led by Schall Law Firm.

Schall Law Firm Invites PEPG Investors to Participate in Class Action Against PepGen Inc. #United_States #Los_Angeles #Schall_Law_Firm #Securities_Fraud #PepGen

Hope we see many more examples of this heightened focus on real promising biotech programs.

I had a small position in #PepGen, but did not like them spending most of my $$$ on DMD. Now, investors may consider capitalizing it again.

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update BOSTON, May 28, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies, today announced that based on the levels of dystrop...

Glad to see #PepGen focus resources on promising type 1 myotonic dystrophy oligo by getting out of DMD:

finance.yahoo.com/news/pepgen-...

PepGen nos comparte en su boletín del primer trimestre de 2025 las actualizaciones de sus ensayos clínicos para la DMD y otras actividades.

Visite la página del estudio CONNECT1-EDO51 en Clinicaltrials.gov

#TheAkariFoundation #DistrofiaMuscularDeDuchenne #duchenneenespañol #PepGen

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy🎉

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #pepgen #connect2 #edo51